| Literature DB >> 35096102 |
Dongmei Wang1, Yue Jiang1, Jiaxing Feng2, Jingshu Gao1, Jinlan Yu3, Jing Zhao4, Pihong Liu1, Yaguang Han1.
Abstract
Pelvic inflammatory disease (PID), a common infectious disease of the female reproductive tract, is mainly characterized by abdominal/pelvic pain and tenderness of the uterus, cervix, or adnexa on physical exam. In recent years, its incidence has gradually increased yearly due to numerous factors, including sexually transmitted diseases and intrauterine operations. Based on self-report of PID in the National Health and Nutrition Examination Survey (NHANES) 2013-2014 survey, PID impacts approximately 2.5 million women in the US during their reproductive age. Although empiric treatments such as antibiotics or surgery could alleviate the related symptoms of PID, its unsatisfactory obstetric outcome and high relapse bring heavy physical and psychological burden to women. Complementary and alternative medicine (CAM), a complementary therapy other than Western medicine with a complete theoretical and practical system, has been attached to importance in the world due to its remarkable efficacy. More people are accepting and trying to use CAM to treat gynecological diseases, including infertility, polycystic ovary syndrome, and PID, but its efficacy and mechanism are still controversial. This article reviews the previous literature systematically focusing on the effectiveness, safety, and mechanism of CAM in the treatment of PID to provide an evidence-based basis for the clinical application of CAM in patients with PID.Entities:
Year: 2022 PMID: 35096102 PMCID: PMC8791705 DOI: 10.1155/2022/1364297
Source DB: PubMed Journal: Evid Based Complement Alternat Med ISSN: 1741-427X Impact factor: 2.629
The RCTs of effective CHM formula for PID with oral administration.
| Study ID | Design | Sample size | Interventions | Outcomes | Composition | Limitations |
|---|---|---|---|---|---|---|
| [ | RCT | 144 | Treatment arm: | Treatment arm: | Dachaihu Decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 360 | Treatment arm: | Treatment arm: | Gongying Tuling Decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 78 | Treatment arm: Hongteng Baijiang Decoction + levofloxacin + metronidazole | Treatment arm: | Hongteng Baijiang Decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 96 | Treatment arm: | Treatment arm: | Yiqi Huayu Penyan Decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 108 | Treatment arm: Dahuangmudan Decoction + cefoxitin + doxycycline | Treatment arm: | Dahuangmudan Decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 100 | Treatment arm: | Treatment arm: | Self-made Qingre Huayu Decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 118 | Treatment arm: | Treatment arm: | Fuyanshu capsule: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 110 | Treatment arm: | Treatment arm: | Danbai granules: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 96 | Treatment arm: | Treatment arm: | Fuyanning Decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 120 | Treatment arm: | Treatment arm: | Guizhi Fuling pills: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 155 | Treatment arm: | Treatment arm: | Jinying capsules: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 38 | Treatment arm: Penning granule | Treatment arm: | Penning granule: | Not mentioned blindness, drop-out rate, and small sample size |
|
| ||||||
| [ | RCT | 90 | Tongluo Qingre Decoction arm | Tongluo Qingre Decoction arm: | Tongluo Qingre Decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 180 | Treatment arm: pelvic inflammatory decoction | Treatment arm: | Pelvic inflammatory decoction: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 80 | Treatment arm: | Treatment arm: | Shaofu Zhuyu Decoction: | Not mentioned blindness, drop-out rate, and small sample size |
Note. RCT: randomized clinical trial; TFR: total effective rate; RR: recurrence rate. p < 0.05 versus treatment arm.
The RCTs of effective CHMRE for PID.
| Study ID | Design | Sample size | Interventions | Outcomes | Composition | Limitation |
|---|---|---|---|---|---|---|
| [ | RCT | 184 | Control arm: | Control arm: | CHMRE prescription: | Not mentioned drop-out rate |
|
| ||||||
| [ | RCT | 110 | Control arm: | Control arm: | Enema Chinese prescription: | Not mentioned blindness and drop-out rate |
|
| ||||||
| [ | RCT | 90 | Control arm: | Control arm: | Self-made Gynecological Anti-Inflammatory No.1 Decoction: | Not mentioned drop-out rate and small sample size |
|
| ||||||
| [ | RCT | 78 | Control arm: | Control arm: | Self-made pelvic inflammation decoction: | Not mentioned drop-out rate and small sample size |
|
| ||||||
| [ | Case-control study | 70 | Control arm: | Control arm: | Xiaoyan Decoction: | Not mentioned blindness, drop-out rate, and small sample size |
|
| ||||||
| [ | RCT | 92 | Control arm: | Control arm: | Pelvic inflammation recipe: | Not mentioned drop-out rate and small sample size |
|
| ||||||
| [ | RCT | 50 | Control arm: | Control arm: | Pen Yan Qing: | Not mentioned drop-out rate and small sample size |
|
| ||||||
| [ | RCT | 86 | Control arm: | Control arm: | CHMRE: | Not mentioned drop-out rate and small sample size |
|
| ||||||
| [ | RCT | 74 | Control arm: | Control arm: | CHMRE: | Not mentioned drop-out rate and small sample size |
Note. RCT: randomized clinical trial; TFR: total effective rate; RR: recurrence rate, PR: pregnancy rate. P < 0.05 versus treatment arm.
The location, regional anatomy, and innervation of common acupoints for treating PID.
| Acupoint | Location | Muscle | Innervation |
|---|---|---|---|
| CV4 (Guanyuan) | 3 cun below the center of the umbilicus on the lower abdomen and on the anterior midline | Fibrous tissue, linea alba | L1 |
| SP6 (Sanyinjiao) | 3 cun proximal to the medial malleolus | Mm. flexor digitorum longus, tibialis posterior | L4-5, S1-2 |
| EX-CA1 (Zigong) | 4 cun below the umbilicus and 3 cun lateral to the anterior midline | Obliquus internus abdominis, musculus transversus abdominis | T10-L2 |
| CV3 (Zhongji) | 4 cun caudal to the umbilicus | Fibrous tissue, linea alba | L1 |
| ST36 (Zusanli) | 3 cun below ST35, one finger breadth from the anterior crest of the tibia, (front ridge of tibia), between fibula and tibia | Anterior tibial muscle, extensor digitorum longus | L4-5, S1-2 |
| CV6 (Qihai) | 1.5 cun inferior to the center of the umbilicus, on the anterior midline | Fibrous tissue, linea alba | Th11 |
| ST29 (Guilai) | 4 cun inferior to the center of the umbilicus, 2 cun lateral to the anterior midline | M. rectus abdominis | Th6-12 |
| BL32 (Ciliao) | At the 2nd posterior sacral foramen on the sacrum and the posterior ramus of the S2 nerve | Erector spinae | L2-S4 |
| BL23 (Shenshu) | Under the 2nd spinous process of lumbar vertebra, next to 1.5 cun | Erector spinae | L1 |
| SP9 (Yinlingquan) | Below medial tibia condyle | M. gastrocnemius | S1-2 |